Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing
Ono Pharmaceutical is immensely dissatisfied over the market expansion re-pricing of its PD-1 inhibitor Opdivo (nivolumab) under the so-called “spillover” rule in the FY2024 price reform, the company told Jiho on January 17. The comment came after the Central Social…
To read the full story
Related Article
BUSINESS
- Jardiance Takes Top Spot in Four Promotion Channels in July: Intage
September 9, 2026
- Rohto Develops Low-Concentration Azelaic Acid Formulation
September 9, 2026
- Kyowa Kirin’s nAMD Med Misses Mark in Global PII Study
September 9, 2026
- AstraZeneca, Kyushu Electric Power Unit Pilot EV Charging Service
September 9, 2026
- Kineret Could Bring Earlier Remission in Still’s Disease: Expert
September 8, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…